Bronchogen Dosage Guide

Standard Bioregulator Dosing: Understanding the Khavinson Precedent

Bronchogen dosing follows the Khavinson Institute's established protocol for peptide bioregulators, which differs significantly from conventional pharmaceutical dosing. Rather than seeking dose-dependent increases in effect (the typical pharmacological paradigm), bioregulator dosing aims for the minimal amount necessary to signal target tissue toward functional restoration. This principle reflects the epigenetic mechanism of action: bioregulators carry biological information, not pharmacologically active substances requiring dose escalation for effect.

The standard recommended dose is 10 mg daily, administered as a single capsule. This dose has been used consistently across decades of research and clinical application in Russia and Eastern Europe, providing a well-established safety and efficacy baseline.

Standard Commercial Bronchogen: 10 mg Capsule Format

Most Bronchogen products are available as capsules containing 10 mg of the peptide (Ala-Glu-Asp) plus inert excipients (cellulose, magnesium stearate, etc.). The capsule format offers advantages over powder: ease of dosing, stability, and precise quantity per dose.

Standard dosing regimens:

• 1 capsule daily (10 mg/day): Recommended starting dose for most individuals. Taken once daily, preferably with a meal to enhance absorption and minimize any gastric irritation. This is the dose used in most clinical research.
• 1 capsule twice daily (20 mg/day): For individuals with severe respiratory pathology, those who had minimal response to 10 mg, or those seeking maximum tissue remodeling stimulus. Double-dosing remains safe and is supported by research.
• Below 10 mg (partial capsules): Not practical for capsule format; users should stick to full capsules (10 mg) rather than opening and using partial contents.

Timing considerations:

• Once-daily dosing: Take in the morning or early afternoon with a meal. Consistent timing aids compliance and may optimize absorption.
• Twice-daily dosing: Take one capsule with breakfast and one with lunch or dinner. Spacing doses 8–12 hours apart distributes the signaling stimulus throughout the day.
• With food: Taking Bronchogen with meals (particularly meals containing some fat or protein) enhances absorption. Fasting absorption is possible but suboptimal.
• With adequate hydration: Swallow capsule with at least 8 oz of water to ensure proper swallowing and GI transit.

Comparing Standard Bioregulator Doses With Clinical Research Protocols

Bronchogen doses used in published clinical research provide historical context and reassurance about safety across a dose range:

Russian clinical studies (1990s–2010s):

• Low-dose protocols: 5–10 mg daily for 10–14 days showed significant respiratory improvements in chronic bronchitis and smokers.
• Standard protocols: 10 mg daily for 10–20 days produced robust improvements in COPD, asthma, and post-viral respiratory dysfunction.
• High-dose protocols: 20 mg daily for 20 days showed maximal tissue remodeling effects but no additional safety concerns compared to 10 mg; cost-benefit slightly favored 10 mg for most conditions.
• Extended protocols: Some studies extended beyond 20 days (up to 30 days continuous), but this was less commonly used because 20 days + rest period proved more effective than 30 days continuous (supporting the cycling principle).

Key finding from research: The 10 mg daily dose emerged as the optimal balance between efficacy and practicality. Increasing to 20 mg daily produces marginally better results but at doubled cost, making it primarily useful for severe pathology rather than routine use.

Dose Adjustments Based on Individual Factors

While the standard 10 mg dose is appropriate for most users, individual optimization is appropriate in specific contexts:

Factors suggesting potentially higher dosing (20 mg/day):

• Severe COPD with significant airflow obstruction (FEV1 < 40% predicted).
• Heavy/current smokers with extensive smoking history (40+ pack-years).
• Severe post-viral respiratory dysfunction (long COVID with persistent dyspnea/cough).
• Age > 70 years (slower tissue regeneration may benefit from stronger signaling).
• Poor initial response to 10 mg dose in first cycle (see minimally responsiveness to suggest higher dose in cycle 2).
• Desire for maximal tissue remodeling in shortest time (e.g., preparing for athletic competition).

Factors suggesting potentially lower dosing (5–10 mg/day or reduced frequency):

• Mild respiratory symptoms (occasional cough, minimal dyspnea).
• First-time bioregulator use (start conservative to assess tolerance).
• Significant side effects with standard dosing (excessive mucus mobilization, GI upset).
• Excellent response to 10 mg in previous cycle (may not need higher dose; maintain successful protocol).
• Cost constraints (10 mg is more economical than 20 mg).

Route of Administration and Bioavailability

Bronchogen is administered orally as a capsule. The peptide is absorbed through the gastrointestinal tract and enters systemic circulation, though some local benefit may also occur as the capsule transits the respiratory-adjacent tissues in the GI tract.

Absorption and bioavailability:

• Oral bioavailability of peptides: Short peptides like the Ala-Glu-Asp tripeptide have moderate oral bioavailability (estimated 30–50% due to peptidase degradation in the GI lumen). However, bioregulator mechanism doesn't require intact circulating peptide—local epithelial signaling and some systemic distribution suffice.
• Capsule dissolution: The capsule typically dissolves in the stomach within 10–15 minutes, releasing the peptide into the acidic gastric environment.
• GI protection: Some Bronchogen products include enteric coatings to protect the peptide from stomach acid and allow release in the small intestine, theoretically improving bioavailability. Standard formulations work adequately without this protection.
• Peak effect timing: Respiratory benefits begin within 5–10 days of starting daily dosing (suggesting sufficient absorption to produce systemic and local effects).

Dose Duration and Total Exposure Across a Cycle

Understanding total peptide exposure during a cycle helps contextualize dosing decisions:

Example: 10-day cycle at 10 mg daily

• Total peptide administered: 10 days × 10 mg/day = 100 mg over the cycle.
• Estimated absorbed (assuming 40% bioavailability): ~40 mg systemically.
• Local delivery to bronchial tissue: additional mechanism via GI epithelium transit + some peptide metabolites.

Example: 20-day cycle at 10 mg daily

• Total peptide administered: 20 days × 10 mg/day = 200 mg over the cycle.
• Extended signaling duration allows deeper tissue remodeling (as seen in clinical outcomes).

Example: 10-day cycle at 20 mg daily

• Total peptide administered: 10 days × 20 mg/day = 200 mg (same as 20-day at 10 mg).
• Allows concentrated signaling in shorter duration; useful if time-limited or seeking rapid response.
• May produce stronger mucus mobilization phase (more coughing) due to higher instantaneous dose.

Safety Across Tested Dosing Ranges

Bronchogen (Ala-Glu-Asp tripeptide) has been used safely at doses ranging from 5–30 mg daily for periods up to 30 days in clinical research. No dose-dependent toxicity has been documented:

Safety profile:

• No serious adverse effects: Across all dose levels, no serious organ toxicity, allergic reactions, or systemic harm has been reported.
• No dose-response toxicity: Doubling dose (from 10 to 20 mg) does not increase adverse effect frequency or severity.
• Minor side effects rare: Occasional mild GI upset or temporary headache reported in <2% of users; unrelated to dose level.
• Contraindications minimal: Only pregnancy (lack of data), active anaphylaxis-level peptide allergy, and possibly uncontrolled autoimmune disease (theoretical concern about immune modulation) warrant avoidance.

The safety window is wide, meaning dose optimization can be individualized without major safety concerns.

Reconstitution and Storage (If Using Powder Form)

Some Bronchogen products are available as lyophilized powder rather than capsules. If using powder:

Dosing by weight:

• Weigh powder precisely (typical scale: 10 mg for standard dose).
• Dissolve in water or mix into food/juice immediately before consumption.
• Take on same schedule as capsule form (once or twice daily with meals).

Storage of powder:

• Keep in cool, dry place (room temperature, below 77°F / 25°C is ideal).
• Protect from moisture (sealed, opaque container preferred).
• Stability: lyophilized peptide remains stable for 2–3 years if stored properly; use-by date on packaging should be observed.

Optimizing Absorption and Compliance

Adherence to the dosing schedule is critical for efficacy. Several strategies optimize compliance:

• Set a daily alarm: Phone reminder at the same time daily (e.g., 8 AM with breakfast).
• Use a pill organizer: Pre-sort capsules into weekly compartments at the cycle start to make dosing obvious.
• Link to an existing habit: Take Bronchogen with your morning coffee or with a specific meal to anchor the habit.
• Use mobile app tracking: Mark off doses on a calendar or app to track progress and ensure compliance.
• Purchase/prepare batches in advance: Calculate total capsules needed for the cycle (e.g., 10 caps for 10-day cycle, 20 caps for 20-day cycle) and have them on hand to avoid supply disruptions.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions

Q: Is more Bronchogen (say, 40 mg daily) better?
A: No. Bronchogen works through epigenetic signaling, not dose-dependent pharmacological action. Beyond 20 mg daily, additional peptide doesn't produce additional tissue remodeling. Standard 10 mg or doubled 20 mg doses are optimal; higher doses waste product and money without additional benefit.

Q: What happens if I miss a dose?
A: If you miss one dose, take the next scheduled dose the next day. Do not double up or compensate; missing one dose out of a 10–20 day cycle has minimal impact on overall efficacy. If you miss more than 3 consecutive doses, the cycle's effectiveness is compromised; consider restarting the cycle another time.

Q: Can I take Bronchogen on an empty stomach?
A: While possible, taking with a meal (preferably containing some fat or protein) enhances absorption and reduces any potential mild GI irritation. Fasting absorption is suboptimal due to rapid gastric transit and reduced bioavailability.

Q: Does the time of day matter for dosing?
A: Consistency matters more than specific time. Morning dosing is popular for convenience; evening dosing is equally effective. Choose a time you can adhere to daily. If twice-daily, spacing 8–12 hours apart (e.g., 8 AM and 6 PM) is sensible but not critical.

Q: Can I take other medications with Bronchogen?
A: Yes. Bronchogen does not interact with standard respiratory medications (inhalers, corticosteroids, antibiotics) or other oral medications. Take Bronchogen at least 1–2 hours apart from iron supplements or calcium supplements (which can bind peptides), but spacing from most medications is unnecessary.

Q: What if my Bronchogen capsules are a different strength (e.g., 20 mg per capsule)?
A: Adjust dosing accordingly. If your capsules are 20 mg each, take 0.5 capsule (half) daily for the standard 10 mg dose, or 1 whole capsule for the 20 mg dose. Some products do vary in capsule strength; check the label and adjust accordingly.